The DOI matches its Crossref record.
Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of Antiretroviral‐Naive HIV‐Infected Adults
Abstract
Background. Zidovudine, lamivudine, and efavirenz comprise a highly effective and well-tolerated triple regimen for antiretroviral-naive patients. Evaluating other unique nucleoside reverse-transcriptase inhibitor (NRTI) combinations for long-term viral suppression is desirable. Methods. This multicenter, randomized, double-blind noninferiority clinical trial compared the efficacy and safety of abacavir with that of zidovudine plus lamivudine and efavirenz in 649 antiretroviral-naive HIV-infected patients. The primary objective was a comparison of proportions of patients achieving plasma HIV-1 RNA levels ⩽50 copies/mL through week 48 of the study. Results. At study week 48, 70% of patients in the abacavir group, compared with 69% in the zidovudine group, maintained confirmed plasma HIV-1 RNA levels of ⩽50 copies/mL (in the intent-to-treat exposed population). Virologic failure was infrequent (6% in the abacavir group and 4% in the zidovudine group). There was a significant CD4+ cell response (209 cells/mm3 in the abacavir group and 155 cells/mm3 in the zidovudine group). Safety profiles were as expected. Conclusion. Abacavir provided an effective and durable antiretroviral response that was noninferior to zidovudine, when combined with lamivudine and efavirenz.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Saag, M., Balu, R., Phillips, E., Brachman, P., Martorell, C., Burman, W., Stancil, B., Mosteller, M., Brothers, C., Wannamaker, P., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/529382 · Cited by 425
Self-citationAbacavir–Lamivudine versus Tenofovir–Emtricitabine for Initial HIV-1 Therapy
Sax, P. E., Tierney, C., Collier, A. C., Fischl, M. A., Mollan, K., Peeples, L., Godfrey, C., Jahed, N. C., Myers, L., Katzenstein, D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906768 · Cited by 313
Moyle, G. J., Sabin, C. A., Cartledge, J., Johnson, M., Wilkins, E., Churchill, D., Hay, P., Fakoya, A., Murphy, M., Scullard, G., et al. (2006) · AIDS · doi:10.1097/01.aids.0000247574.33998.03 · Cited by 273
Gupta, R. K., Hill, A., Sawyer, A. W., Cozzi-Lepri, A., von Wyl, V., Yerly, S., Lima, V. D., Günthard, H. F., Gilks, C., & Pillay, D. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70136-7 · Cited by 254
Nunn, A. S., Fonseca, E. M., Bastos, F. I., Gruskin, S., & Salomon, J. A. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040305 · Cited by 142
Metadata
- Authors
- DeJesus, E., Herrera, G., Teofilo, E., Gerstoft, J., Buendia, C. B., Brand, J. D., Brothers, C. H., Hernandez, J., Castillo, S. A., Bonny, T., Lanier, E. R., Scott, T. R., & CNA30024 Study Team
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-10
- Volume
- 39
- Issue
- 7
- Pages
- 1038-1046
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2052332986
- Cited by
- 226
- References
- 0
- FWCI
- 11.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of Antiretroviral‐Naive HIV‐Infected Adults. https://app.cochat.ai/papers/10.1086/424009
- The paper
- DeJesus, E., Herrera, G., Teofilo, E., Gerstoft, J., Buendia, C. B., Brand, J. D., Brothers, C. H., Hernandez, J., Castillo, S. A., Bonny, T., Lanier, E. R., Scott, T. R., & CNA30024 Study Team. (2004). Abacavir versus Zidovudine Combined with Lamivudine and Efavirenz, for the Treatment of Antiretroviral‐Naive HIV‐Infected Adults. Clinical Infectious Diseases. https://doi.org/10.1086/424009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
